FRMD8 and neoplasm: We used an allograft model based on the subcutaneous injection of murine Lewis lung carcinoma (LLC) tumor cells into immunocompetent WT versus iTAP/Frmd8 KO mice (Fig 4A), to assess the impact of iTAP/Frmd8 loss in the tumor niche on the growth of WT LLC cells (Mendonça et al, 2019).